* life expectancy less than 3 months before covid-19 at the discretion of the investigator * invasive mechanical ventilation ≥ 72 hours at time-point of randomization * resuscitation \> 45 minutes * hypersensitivity to the active substance, to adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies * uncontrolled haematological/ oncological malignancies * pre-existing severe chronic liver disease (i.e. child-pugh c) before covid-19 hospitalization * absolute neutropenia \<500 per μl

* life expectancy less than 3 months before covid-19 at the discretion of the investigator * invasive mechanical ventilation ≥ 72 hours at time-point of randomization * resuscitation \> 45 minutes * hypersensitivity to the active substance, to adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies * uncontrolled haematological/ oncological malignancies * pre-existing severe chronic liver disease (i.e. child-pugh c) before covid-19 hospitalization * absolute neutropenia \<500 per μl

life expectancy less than 3 months before covid-19 at the discretion of the investigator invasive mechanical ventilation ≥ 72 hours at time-point of randomization resuscitation > 45 minutes hypersensitivity to the active substance, to adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies uncontrolled haematological/ oncological malignancies pre-existing severe chronic liver disease (i.e. child-pugh c) before covid-19 hospitalization absolute neutropenia <500 per μl

life expectancy less than 3 months before covid-19 at the discretion of the investigator invasive mechanical ventilation ≥ 72 hours at time-point of randomization resuscitation > 45 minutes hypersensitivity to the active substance, to adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies uncontrolled haematological/ oncological malignancies pre-existing severe chronic liver disease (i.e. child-pugh c) before covid-19 hospitalization absolute neutropenia <500 per μl

life expectancy less than 3 months before covid-19 at the discretion of the investigator invasive mechanical ventilation ≥ 72 hours at time-point of randomization history of severe asthma, atopic allergy, severe immune or chronic inflammatory conditions (e.g. systemic lupus erythematosus) resuscitation > 45 minutes hypersensitivity to the active substance, to adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies currently receiving systemic chemotherapy and/or radiotherapy pre-existing severe chronic liver disease (i.e. child-pugh c) before covid-19 hospitalization pre-existing dialysis therapy before covid-19 hospitalization

life expectancy less than 3 months before covid-19 at the discretion of the investigator invasive mechanical ventilation ≥ 72 hours at time-point of randomization history of severe asthma, atopic allergy, severe immune or chronic inflammatory conditions (e.g. systemic lupus erythematosus) resuscitation > 45 minutes hypersensitivity to the active substance, to adrecizumab or any of its excipients, or known serious hypersensitivity to other monoclonal antibodies currently receiving systemic chemotherapy and/or radiotherapy pre-existing severe chronic liver disease (i.e. child-pugh c) before covid-19 hospitalization pre-existing dialysis therapy before covid-19 hospitalization